SignalTrace

Roflumilast Cream

John Montgomery5 min read

Roflumilast Cream

Roflumilast cream (Zoryve, Arcutis Biotherapeutics) is a once-daily, steroid-free cream for mild-to-moderate Atopic Dermatitis. Roflumilast blocks phosphodiesterase-4 (PDE4), the same enzyme targeted by Crisaborole ointment. Blocking PDE4 inside immune cells is thought to calm the cytokine release behind eczema inflammation. The drug was first used as a tablet for COPD (Daxas in the EU and UK). As a cream it sits with Ruxolitinib Cream, Tapinarof Cream and Topical Calcineurin Inhibitors as a steroid-sparing alternative to Topical Corticosteroids. It does not cause Skin Atrophy. There is no traditional use, because this is a new synthetic drug.

Roflumilast Cream [treats] Atopic Dermatitis Roflumilast Cream [relates] Crisaborole Roflumilast Cream [relates] Topical Corticosteroids

Licensing for toddlers. The FDA label (effective 20 July 2026) has two eczema strengths. Cream 0.15% is for adults and children 6 years and older. A weaker 0.05% cream is licensed for children aged 2 to 5. It was approved on 6 October 2025, a week before its target date (Contemporary Pediatrics). Both strengths are applied once daily. The weaker strength exists because, in a pharmacokinetic study, 2- to 5-year-olds absorbed about 3.2 to 5.2 times as much of the drug from the 0.15% cream as adolescents did. Under 2 years the cream is unlicensed. In July 2026 the FDA accepted an application to extend the 0.05% cream to infants aged 3 to 24 months, with a decision due by 23 February 2027 (Medscape). That application rests on open-label phase 1–2 data: 101 infants, 34.4% clear or almost clear at week 4. Neither the European Medicines Agency nor the UK has authorised roflumilast cream. The EMA medicines register lists only roflumilast tablets for COPD. The UK emc lists only Daxas and generic tablets (MHRA product search could not be loaded to confirm).

FDA [regulates] Roflumilast Cream European Medicines Agency [relates] Roflumilast Cream MHRA [relates] Roflumilast Cream

Strength of evidence. INTEGUMENT-PED was the pivotal toddler trial: 652 children aged 2–5 with mild-to-moderate AD (median age 3, mean 22% of body surface affected, 53% with facial eczema). They applied roflumilast 0.05% or a vehicle cream once daily for 4 weeks. On the 0.05% cream, 25.4% reached “clear or almost clear” with a 2-grade improvement, against 10.7% on vehicle (difference 14.9%). EASI-75 was 39.4% against 20%. In the open-label extension, 353 children aged 2–5 used it for 52 weeks without new safety signals (FDA label). The trials were short, with no head-to-head comparison against a mild topical steroid. The AAD Pediatric Guideline 2026 makes a strong recommendation for roflumilast in mild-to-moderate AD from age 2, on moderate-certainty evidence (3 RCTs). It notes less application-site burning than crisaborole, and that twice-weekly proactive use kept skin clearer in a 52-week extension. Roflumilast is not in NICE CG57.

AAD Pediatric Guideline 2026 [supports] Roflumilast Cream Roflumilast Cream [supports] Weekend Therapy

Conflict: [AAD Pediatric Guideline 2026, Tables V–VI] recommends roflumilast 0.15% cream for children aged 2 years and older. [FDA ZORYVE label, effective 2026-07-20] licenses 0.15% only from age 6, and 0.05% for ages 2–5. Unresolved: possibly a manuscript error, because the cited toddler trial used 0.05%. Added to open_questions.

Toddler safety. In INTEGUMENT-PED, side effects more common than with vehicle were upper respiratory infection (4.1% vs 1.4%), diarrhoea (2.5% vs 0.5%), vomiting (2.1% vs 0%), rhinitis (1.6%), Conjunctivitis (1.4%) and headache (1.1%). All were low-frequency. The US label has no boxed warning, unlike Ruxolitinib Cream and the Topical Calcineurin Inhibitors. Parents should use the 0.05% strength for under-6s. A sibling’s or parent’s 0.15% or 0.3% tube is not interchangeable, because toddlers absorb more drug.

Roflumilast Cream [relates] Conjunctivitis Roflumilast Cream [relates] Ruxolitinib Cream

Use the toddler strength

Zoryve comes as 0.05%, 0.15% and 0.3% creams and a 0.3% foam. Only 0.05% is licensed for eczema in children aged 2–5. Higher strengths give much higher blood levels in small children (FDA label).

What parents report. Reports from parents are few, and most concern school-age children (evidence: anecdotal). One parent of a 6-year-old said tacrolimus, pimecrolimus and crisaborole had all failed. Zoryve then controlled about 85% of new spots with no side effects, though the worst recurring patches still needed a steroid (evidence: anecdotal). Another parent said it was the only thing that “dramatically helped” their daughter, but the rash came back whenever they tried to stop, and they worried about using a new drug indefinitely (evidence: anecdotal). This vault found no parent reports specific to the 0.05% toddler strength.

Parent Experiences [relates] Roflumilast Cream

Connections

Graph View

Backlinks